Sunpeaks Ventures Acquires Bryce Rx Laboratories for $1.1M
Sunpeaks Ventures, Inc. (OTCBB: SNPK) (PINKSHEETS: SNPK) announces the acquisition of Bryce Rx Laboratories of Stamford, CT. Bryce Rx Laboratories, Inc, specializes in the formulation of drugs that are not commercially available, require alternate delivery systems and dosing changes. Services include customized formulations for Urology and Women's Health. Bryce also offers specialized formulations for Dermatology, Pain Management, as well as formulations for Veterinary use.
The acquisition of Bryce will allow the Company to expand nationally in the compounding space and further diversify the revenue stream. Based upon Bryce's current operations, the acquisition will add approximately $1.5M in revenue and is expected to improve overall margins. Sunpeaks Ventures plans to quickly grow the license base of Bryce, expand the sales force, and expand the product offers through facility improvements and capital investments. The purchase price was $1.1 million.
Sunpeaks Ventures, Inc. and its wholly owned subsidiary Healthcare Distribution Specialists, LLC ("HDS"), is distributor of specialty drugs and over-the-counter ("OTC") branded multivitamins to the healthcare provider market. HDS also owns and markets Clotamin®, a specialized over-the-counter multivitamin product designed for use by patients also on Warfarin®, a popular blood thinner that has a long list of known adverse drug and food interactions.
For additional information, please visit www.sunpeaksventures.com.